Evanston, Illinois-based Naurex, a developer of drugs that treat depression and other central nervous system disorders, has closed $80 million in Series C funding. The investors included Cowen Investments, EcoR1 Capital, Goudy Park Capital, Portola Capital Partners, Sabby Capital, Adams Street Partners, Baxter Ventures and Druid BioVentures.
The capital infusion will be used for ongoing clinical drug trials, Naurex said.
This investment follows the company’s $25 million Series C funding announced last May. The investors in that round were not named. In December 2012, Naurex raised $38 million in a Series B funding round led by Baxter Ventures. Other backers included DruidBioVentures, Genesys Capital, PathoCapital, Latterell Venture Partners, Adams Street Partners and Savitr Capital.
Norbert G. Riedel is currently serving as CEO and president of Naurex.
Photo courtesy of Shutterstock.